Faes Farma S.A (FAE) | Financial Analysis & Statements
Faes Farma S.A. Large-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
314.3M
Gross Profit
200.9M
63.93%
Operating Income
27.3M
8.67%
Net Income
27.5M
8.74%
EPS (Diluted)
€0.09
Balance Sheet Metrics
Total Assets
1.3B
Total Liabilities
596.3M
Shareholders Equity
745.6M
Debt to Equity
0.80
Cash Flow Metrics
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Faes Farma S.A Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 610.5M | 493.6M | 451.2M | 438.8M | 398.6M |
| Cost of Goods Sold | 214.6M | 167.1M | 154.0M | 156.7M | 146.2M |
| Gross Profit | 395.9M | 326.5M | 297.1M | 282.0M | 252.4M |
| Gross Margin % | 64.9% | 66.1% | 65.9% | 64.3% | 63.3% |
| Operating Expenses | |||||
| Research & Development | - | 5.8M | 5.2M | 3.7M | 3.9M |
| Selling, General & Administrative | - | 65.8M | 57.4M | 52.5M | 49.3M |
| Other Operating Expenses | 156.2M | 109.2M | 35.8M | 35.0M | 27.4M |
| Total Operating Expenses | 156.2M | 180.8M | 98.4M | 91.2M | 80.6M |
| Operating Income | 88.8M | 108.5M | 103.7M | 102.2M | 97.8M |
| Operating Margin % | 14.6% | 22.0% | 23.0% | 23.3% | 24.5% |
| Non-Operating Items | |||||
| Interest Income | 2.3M | 1.7M | 1.1M | 253.0K | 23.0K |
| Interest Expense | 5.8M | 433.0K | 383.0K | 263.0K | 216.0K |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 85.4M | 107.6M | 102.9M | 101.4M | 93.0M |
| Income Tax | 5.8M | -3.5M | 11.2M | 12.0M | 10.5M |
| Effective Tax Rate % | 6.7% | -3.3% | 10.8% | 11.8% | 11.3% |
| Net Income | 79.7M | 111.1M | 91.7M | 89.4M | 82.4M |
| Net Margin % | 13.0% | 22.5% | 20.3% | 20.4% | 20.7% |
| Key Metrics | |||||
| EBITDA | 119.9M | 129.8M | 123.3M | 121.3M | 114.7M |
| EPS (Basic) | €0.26 | €0.36 | €0.30 | €0.28 | €0.27 |
| EPS (Diluted) | €0.25 | €0.36 | €0.30 | €0.28 | €0.26 |
| Basic Shares Outstanding | 306269231 | 309333333 | 309976691 | 317403692 | 302670130 |
| Diluted Shares Outstanding | 306269231 | 309333333 | 309976691 | 317403692 | 302670130 |
Income Statement Trend
Faes Farma S.A Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 117.3M | 64.2M | 34.6M | 66.4M | 70.3M |
| Short-term Investments | 12.8M | 7.9M | 13.1M | 17.7M | 3.2M |
| Accounts Receivable | 152.5M | 111.0M | 104.1M | 101.6M | 102.1M |
| Inventory | 185.0M | 141.6M | 128.7M | 114.0M | 106.5M |
| Other Current Assets | - | - | - | - | - |
| Total Current Assets | 482.4M | 333.7M | 290.3M | 313.2M | 293.7M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 353.3M | 1.5M | 1.9M | 59.6M | 2.2M |
| Goodwill | 716.4M | 240.7M | 241.1M | 230.5M | 236.1M |
| Intangible Assets | 199.4M | 127.6M | 128.4M | 126.9M | 129.4M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | - | - | - | - | 4.0K |
| Total Non-Current Assets | 859.5M | 519.4M | 486.3M | 413.9M | 351.4M |
| Total Assets | 1.3B | 853.1M | 776.6M | 727.2M | 645.1M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 83.4M | 46.8M | 35.4M | 36.6M | 37.9M |
| Short-term Debt | 26.6M | 20.1M | 20.0M | 28.3M | 14.3M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 184.9M | 103.5M | 87.3M | 94.4M | 79.3M |
| Non-Current Liabilities | |||||
| Long-term Debt | 373.7M | 2.7M | 4.4M | 4.4M | 2.2M |
| Deferred Tax Liabilities | 24.0M | 15.6M | 16.9M | 21.1M | 21.7M |
| Other Non-Current Liabilities | - | - | 241.0K | 35.0K | 157.0K |
| Total Non-Current Liabilities | 411.4M | 23.0M | 25.9M | 30.3M | 28.5M |
| Total Liabilities | 596.3M | 126.5M | 113.2M | 124.7M | 107.8M |
| Equity | |||||
| Common Stock | 31.6M | 31.6M | 31.6M | 31.1M | 29.7M |
| Retained Earnings | 194.6M | 209.0M | 165.8M | 147.5M | 127.0M |
| Treasury Stock | 10.9M | 11.0M | 11.0M | 5.3M | 5.3M |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 745.6M | 726.6M | 663.4M | 602.4M | 537.3M |
| Key Metrics | |||||
| Total Debt | 400.3M | 22.9M | 24.4M | 32.7M | 16.4M |
| Working Capital | 297.5M | 230.3M | 203.0M | 218.8M | 214.4M |
Balance Sheet Composition
Faes Farma S.A Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 85.4M | 107.6M | 91.7M | 89.4M | 82.4M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | - | 747.0K | 774.0K | 146.0K | 0 |
| Working Capital Changes | 0 | -21.5M | -12.3M | -9.9M | -14.7M |
| Operating Cash Flow | 96.6M | 93.5M | 79.6M | 79.6M | 67.9M |
| Investing Activities | |||||
| Capital Expenditures | -21.5M | -39.5M | -95.8M | -68.0M | -51.1M |
| Acquisitions | -272.2M | 0 | -4.5M | 0 | -22.6M |
| Investment Purchases | -5.5M | -7.8M | -8.8M | -21.5M | -1.9M |
| Investment Sales | 199.0K | 13.1M | 18.2M | 2.8M | - |
| Investing Cash Flow | -299.0M | -42.0M | -99.8M | -86.7M | -75.6M |
| Financing Activities | |||||
| Share Repurchases | - | 0 | -17.7M | 0 | 0 |
| Dividends Paid | -55.7M | -48.2M | -14.6M | -18.1M | -13.7M |
| Debt Issuance | - | 0 | 260.0K | 2.3M | 0 |
| Debt Repayment | - | -3.5M | -3.3M | -2.6M | -3.4M |
| Financing Cash Flow | 273.6M | -55.2M | -35.4M | -18.5M | -19.1M |
| Free Cash Flow | 54.8M | 75.9M | -1.2M | 26.1M | 20.2M |
| Net Change in Cash | 71.2M | -3.6M | -55.5M | -25.6M | -26.7M |
Cash Flow Trend
Faes Farma S.A Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
19.60
Forward P/E
14.10
Price to Book
2.05
Price to Sales
2.43
PEG Ratio
14.10
Profitability Ratios
Profit Margin
12.70%
Operating Margin
0.64%
Return on Equity
10.82%
Return on Assets
5.06%
Financial Health
Current Ratio
2.61
Debt to Equity
58.11
Beta
0.32
Per Share Data
EPS (TTM)
€0.25
Book Value per Share
€2.39
Revenue per Share
€2.01
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| FAE | 1.5B | 19.60 | 2.05 | 10.82% | 12.70% | 58.11 |
| Laboratorios | 4.3B | 36.12 | 6.59 | 22.33% | 18.89% | 18.04 |
| Almirall S.A | 2.8B | 58.64 | 1.86 | 3.10% | 4.14% | 23.30 |
| Laboratorio Reig | 220.6M | 45.17 | 1.01 | 2.30% | 1.49% | 42.21 |
| Labiana Health S.A | 49.2M | 42.50 | 7.81 | 23.11% | 1.26% | 998.21 |
| Grifols, S.A | 6.1B | 15.58 | 1.19 | 6.17% | 5.34% | 126.83 |
Financial data is updated regularly. All figures are in the company's reporting currency.





